2025-2034 Acquired Immunodeficiency Syndrome (AIDS) Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Acquired Immunodeficiency Syndrome (AIDS) Industry Market Size Be by 2025?
The market for acquired immunodeficiency syndrome (aids) has experienced robust expansion recently, projected to climb from $32.09 billion in 2024 to $33.75 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.2%. This past growth surge is primarily linked to escalating rates of HIV infection, augmentation of governmental financial backing for HIV therapies, broader implementation of worldwide awareness campaigns, enhancements in diagnostic technologies, and increased endorsement from non-governmental entities.

What's the Long-Term Growth Forecast for the Acquired Immunodeficiency Syndrome (AIDS) Market Size Through 2029?
The market associated with acquired immunodeficiency syndrome (AIDS) is projected to experience significant expansion over the coming years, reaching a valuation of $41.28 billion by 2029, fueled by a compound annual growth rate (CAGR) of 5.2%.This upswing is largely attributable to several key factors, including the surging need for extended-release injectable treatments, the wider uptake of pre-exposure prophylaxis (PrEP), augmented financial commitments to research aimed at curing HIV, the proliferation of remote healthcare options within HIV management, a heightened emphasis on tailoring medical approaches to individual patients, and greater public knowledge regarding the importance of timely HIV detection.During this projection timeframe, prominent trends encompass a movement towards medication protocols involving only one tablet, a growing inclination for HIV therapeutics administered via injection or implant, escalating requirements for technologically driven healthcare tools in managing HIV, intensified exploration into methods for achieving a functional cure for HIV, and the progressively vital application of artificial intelligence in discovering new pharmaceuticals.

View the full report here:
https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report

What Are the Key Growth Drivers Fueling the Acquired Immunodeficiency Syndrome (AIDS) Market Expansion?
Anticipated escalation in the prevalence of HIV infections is forecast to serve as a significant catalyst for the expansion of the acquired immunodeficiency syndrome (AIDS) market moving ahead. The human immunodeficiency virus (HIV) causes this condition by targeting and compromising the immune system, thereby diminishing the body's natural defenses against various illnesses and infections. Factors contributing to the rise in HIV infections include engagement in sexual activity without protection with a carrier, the utilization of shared intravenous equipment, exposure to blood supplies that are not sterile, having numerous sexual partners, or possessing an already compromised immune state or existing sexually transmitted diseases. Management strategies for acquired immunodeficiency syndrome (AIDS) are beneficial for individuals living with HIV infection through several means: fostering prompt identification of the virus, broadening the availability of potent antiretroviral treatments, improving preventative measures, and reinforcing the healthcare infrastructures involved in more effectively containing the virus's transmission. As an illustration, data released in November 2024 by the European Centre for Disease Prevention and Control (ECDC), an agency situated in the European Union, indicated that a cumulative figure of 112,883 new HIV diagnoses were registered across 47 of the 53 nations in the region during 2023, with the European Union/European Economic Area (EU/EEA) alone accounting for 24,731 of these instances. This translates to a general crude rate for HIV diagnoses amounting to 12.7 per 100,000 individuals, marking a 2.4% rise from the 12.4 per 100,000 rate documented the previous year, 2022; consequently, the growing numbers of HIV infections are fueling the trajectory of the acquired immunodeficiency syndrome (AIDS) market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp

What Are the Key Trends Driving Acquired Immunodeficiency Syndrome (AIDS) Market Growth?
Within the sphere of the acquired immunodeficiency syndrome (AIDS) market, leading corporations are concentrating efforts on creating novel therapeutic solutions, notably long-acting injectable medications, which promise enhanced patient adherence, necessitate less frequent administration, and constitute a more practical substitution for taking antiretroviral drugs orally every day. These long-acting injections represent pharmaceuticals delivered through a shot, engineered for a gradual release of their medicinal components over a prolonged duration, thus permitting less recurrent dosage schedules than conventional tablet-based medicines. As an illustration, in January 2025, the United Kingdom's pharmaceutical giant, GSK plc., confirmed receiving endorsement from the European Commission for its combination long-acting injectable therapy, Vocabria (cabotegravir) administered alongside Rekambys (rilpivirine); this regimen is authorized for HIV-positive adolescents aged twelve and above and is delivered via intramuscular means, generally on a one- or two-month cycle contingent upon the prescribed regimen, potentially boosting compliance levels in younger individuals for whom daily pill routines present difficulties.

How Is the Acquired Immunodeficiency Syndrome (AIDS) Market Segmented?
The acquired immunodeficiency syndrome (aids)market covered in this report is segmented -

1) By Type: Human Immunodeficiency Virus 1; Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors; Non-Nucleoside Reverse Transcriptase Inhibitors; Fusion Inhibitors; CCR5 Anatagonists And Post-Attachment Inhibitors; Protease Inhibitors; Integrase Inhibitors; Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral; Parenteral
4) By Application: Hospital Pharmacy; Retail Pharmacy; Other Applications
5) By Distribution Channel: Offline; Online

Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART); Pre-Exposure Prophylaxis (PrEP); Post-Exposure Prophylaxis (PEP); HIV-1 Diagnostic Tests; HIV-1 Vaccine Development; HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2; HIV-2 Diagnostic Tests; HIV-2 Surveillance And Epidemiology; HIV-2 Vaccine Research; Management Of HIV-2 Co-Infections

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp

Which Companies Are Leading the Charge in Acquired Immunodeficiency Syndrome (AIDS) Market Innovation?
Major companies operating in the acquired immunodeficiency syndrome (AIDS) market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatris Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare

Which Regions Are Leading the Global Acquired Immunodeficiency Syndrome (AIDS) Market in Revenue?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.